share_log

Alzamend Neuro | 10-Q: Q2 2025 Earnings Report

Alzamend Neuro | 10-Q: Q2 2025 Earnings Report

Alzamend Neuro | 10-Q：2025财年二季报
美股SEC公告 ·  2024/12/11 16:36

Moomoo AI 已提取核心信息

Alzamend Neuro reported financial results for Q2 fiscal 2025 ended October 31, 2024. Cash increased to $4.1 million from $376,048 at April 30, 2024. Net loss narrowed to $1.4 million compared to $2.9 million in Q2 2024. Research and development expenses decreased 84% to $311,088, while general and administrative expenses rose 16% to $1.0 million.The company advanced its clinical programs for AL001 and ALZN002. It completed a Phase IIA trial for AL001 in Alzheimer's disease and plans to initiate five new clinical trials. For ALZN002, Alzamend is pursuing a new contract research organization to continue its Phase I/IIA trial in Alzheimer's patients.Alzamend strengthened its financial position through preferred stock sales and an at-the-market offering. It raised $7.1 million from Series A convertible preferred stock issuances and $1.2 million from common stock sales. Management believes current funding is sufficient for planned operations over the next 12 months, though additional capital may be needed for long-term clinical development.
Alzamend Neuro reported financial results for Q2 fiscal 2025 ended October 31, 2024. Cash increased to $4.1 million from $376,048 at April 30, 2024. Net loss narrowed to $1.4 million compared to $2.9 million in Q2 2024. Research and development expenses decreased 84% to $311,088, while general and administrative expenses rose 16% to $1.0 million.The company advanced its clinical programs for AL001 and ALZN002. It completed a Phase IIA trial for AL001 in Alzheimer's disease and plans to initiate five new clinical trials. For ALZN002, Alzamend is pursuing a new contract research organization to continue its Phase I/IIA trial in Alzheimer's patients.Alzamend strengthened its financial position through preferred stock sales and an at-the-market offering. It raised $7.1 million from Series A convertible preferred stock issuances and $1.2 million from common stock sales. Management believes current funding is sufficient for planned operations over the next 12 months, though additional capital may be needed for long-term clinical development.
Alzamend Neuro报告了截至2024年10月31日的2025财政年第二季度的财务结果。现金从2024年4月30日的376,048美元增加至410万美元。净亏损缩小至140万美元，而2024年第二季度为290万美元。研发费用减少了84%，降至311,088美元，而管理费用上涨了16%，达到100万美元。该公司推进了AL001和ALZN002的临床项目。它在阿尔茨海默病方面完成了AL001的二期A期试验，并计划启动五项新的临床试验。对于ALZN002，Alzamend正在寻求新的合同研究组织，以继续在阿尔茨海默病患者中进行其一期/二期A期试验。Alzamend通过优先股销售和市场发行加强了财务状况。它通过A系列可转换优先股发行筹集了710万美元，并通过普通股销售筹集了120万美元。管理层认为目前的资金足以支持未来12个月的计划运营，尽管长期临床开发可能需要额外资金。
Alzamend Neuro报告了截至2024年10月31日的2025财政年第二季度的财务结果。现金从2024年4月30日的376,048美元增加至410万美元。净亏损缩小至140万美元，而2024年第二季度为290万美元。研发费用减少了84%，降至311,088美元，而管理费用上涨了16%，达到100万美元。该公司推进了AL001和ALZN002的临床项目。它在阿尔茨海默病方面完成了AL001的二期A期试验，并计划启动五项新的临床试验。对于ALZN002，Alzamend正在寻求新的合同研究组织，以继续在阿尔茨海默病患者中进行其一期/二期A期试验。Alzamend通过优先股销售和市场发行加强了财务状况。它通过A系列可转换优先股发行筹集了710万美元，并通过普通股销售筹集了120万美元。管理层认为目前的资金足以支持未来12个月的计划运营，尽管长期临床开发可能需要额外资金。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间